View Older Stories View More Recent Stories

Apr 10, 2024 07:30AM BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Apr 7, 2024 01:15PM BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardi
Mar 20, 2024 07:30AM BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Mar 4, 2024 02:30AM BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
Feb 22, 2024 07:30AM BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
Feb 7, 2024 07:35AM BridgeBio Pharma (BBIO) and Kyowa Kirin Partner $100M Upfront Payment for Exclusive License on Infigratinib in Skeletal Dysplasias in Japan
Feb 7, 2024 07:34AM BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan
Feb 6, 2024 07:30AM BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Feb 5, 2024 07:32AM BridgeBio Pharma (BBIO) Announces FDA Acceptance of New Drug Application for Acoramidis
Feb 5, 2024 07:30AM BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR
Feb 2, 2024 07:00AM BridgeBio Pharma (BBIO) Reports Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients
Feb 2, 2024 07:00AM BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial
Jan 30, 2024 07:00AM Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics
Jan 18, 2024 07:00AM BridgeBio Pharma (BBIO) Secures Up to $1.25B in Capital to Accelerate the Development and Launch of Genetic Medicines
Jan 18, 2024 07:00AM BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic Medicines
Jan 10, 2024 05:16PM BridgeBio Pharma (BBIO) Reports Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis
Jan 10, 2024 05:15PM BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of
Jan 10, 2024 07:30AM BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Jan 3, 2024 04:30PM BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference
Jan 3, 2024 07:30AM BridgeBio Pharma (BBIO) announces FDA clearance of IND application for BBO-8520, a first-in-class direct inhibitor of KRASG12C
Jan 3, 2024 07:30AM BridgeBio announces FDA clearance of IND application for BBO-8520, a first-in-class direct inhibitor of KRASG12C (ON)
Dec 13, 2023 07:30AM BridgeBio Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with Achondroplasia
Dec 8, 2023 07:30AM BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Dec 5, 2023 07:45AM BridgeBio Pharma (BBIO) Announces Submission of NDA to FDA for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy
Dec 5, 2023 07:44AM BridgeBio Pharma Announces Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (A
Nov 13, 2023 05:34AM BridgeBio Pharma (BBIO) Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis
Nov 12, 2023 10:30AM BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
Nov 9, 2023 07:30AM BridgeBio Pharma to Present Additional Data from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American Heart Association (AHA) Scientific Sessi
Nov 8, 2023 07:30AM BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Nov 2, 2023 07:30AM BridgeBio Pharma Reports Third Quarter 2023 Financial Results and Business Update
Oct 11, 2023 07:30AM BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 10, 2023 07:30AM BridgeBio Pharma (BBIO) Announces NEJM Publication of Positive Encaleret Proof-of-Concept Phase 2b Results in Patients with Autosomal Dominant Hypocalcemia Type 1
Oct 10, 2023 07:30AM BridgeBio Pharma Announces New England Journal of Medicine Publication of Positive Encaleret Proof-of-Concept Phase 2b Results in Patients with Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Oct 9, 2023 07:30AM BridgeBio Pharma (BBIO) Reports Positive Long-Term Data from an Ongoing Phase 2 Study
Oct 9, 2023 07:30AM BridgeBio Pharma Shares Positive Long-Term Data from an Ongoing Phase 2 Study, which Support the Potential Use of Glycosylated Alpha-dystroglycan (⍺DG) Levels as a Surrogate Endpoint in Limb-girdle
Sep 8, 2023 07:30AM BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Sep 7, 2023 07:30AM BridgeBio Pharma to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
Sep 6, 2023 07:30AM BridgeBio Pharma Inc. (BBIO) Reports Positive FDA and EMA Feedback on Regulatory Path for a Pivotal Phase 3 Trial of Infigratinib
Sep 6, 2023 07:30AM BridgeBio Pharma Announces Positive Feedback from the U.S. FDA and EU EMA on the Regulatory Path for a Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia
Aug 28, 2023 05:07AM BridgeBio Pharma (BBIO) Reports Detailed Positive Results from Phase 3 ATTRibute-CM Trial of acoramidis
Aug 27, 2023 06:15AM BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) at European Society of Cardiology Congress 2
Aug 24, 2023 04:01PM BridgeBio Pharma to Present Detailed Results from the Phase 3 ATTRibute Study in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) at European Society of Cardiology (ESC) Congress 2023
Aug 4, 2023 07:30AM BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Aug 3, 2023 07:30AM BridgeBio Pharma Reports Second Quarter 2023 Financial Results and Business Update
Jul 31, 2023 07:31AM BridgeBio Pharma (BBIO) Announces Opportunity for Accelerated Approval Pathway in Limb-girdle Muscular Dystrophy Type 2I (LGMD2I/R9)
Jul 31, 2023 07:30AM BridgeBio Pharma Announces Opportunity for Accelerated Approval Pathway in Limb-girdle Muscular Dystrophy Type 2I (LGMD2I/R9) Based on Glycosylated Alpha-dystroglycan (⍺DG) Levels and Announces Firs
Jul 18, 2023 07:30AM BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Jul 17, 2023 07:03AM BridgeBio Pharma Inc. (BBIO) Reports Consistently Positive Results from Phase 3 ATTRibute-CM study of Acoramidis
Jul 17, 2023 07:00AM BridgeBio announces consistently positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)
Jul 14, 2023 04:01PM BridgeBio to Host Investor Call to Share Topline 30-month Results from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy on July 17, 2023
View More Recent Stories View Older Stories